Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Primary Vaccination Study to Evaluate Immunogenicity, Safety and Reactogenicity of 3 Doses of GSK Biologicals/Finlay's Meningococcal B Candidate Vaccine Given Intramuscularly Using Either 0-2-4 Month or 0-1-6 Month Schedule to Healthy Subjects Aged 12-18 Years

NCT00137917 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00137917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00137917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Primary Vaccination Study to Evaluate Immunogenicity, Safety and Reactogenicity of 3 Doses of GSK Biologicals/Finlay's Meningococcal B Candidate Vaccine Given Intramuscularly Using Either 0-2-4 Month or 0-1-6 Month Schedule to Healthy Subjects Aged 12-18 Years
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2002
Completion date
June 30, 2003
Enrollment
478 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal